Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang...